Physician profile
William M Jacobs
NPI 1265882260
$2,090.71
in general payments reported to CMS, 2019-2025
29 companies · $662 in 2025
The $662 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $137 · 2021: $400 · 2022: $33.88 · 2024: $471 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $474.90 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $266.66 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $168.36 | 2019-2025 | |
| Amarin Pharma, INC. | $122.37 | 2020-2021 | |
| Exact Sciences Corporation | $119.17 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $117.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $108.61 | 2024-2025 | Airsupra |
| Csl Behring | $99.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.79 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $62.13 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $53.87 | 2021 | |
| Abbott Laboratories | $49.15 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $40.91 | 2022-2024 | |
| Glaxosmithkline, LLC. | $36.71 | 2024 | Trelegy Ellipta, Shingrix, Boostrix |
| Biohaven Pharmaceuticals, INC. | $30.33 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $27.94 | 2025 | Pyrukynd |
| Inspire Medical Systems, INC. | $24.29 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $19.28 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $19.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.24 | 2022 | |
| Gilead Sciences, INC. | $17.88 | 2025 | |
| Axsome Therapeutics, INC. | $17.50 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $16.80 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $16.63 | 2025 | Givlaari |
| Actelion Pharmaceuticals US, INC. | $15.61 | 2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $14.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2024 | Eliquis |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.